RxDoctor Payments Data

Shylasree Krishnan, MD

Internal Medicine · Rochester, NYNPI 1023048543

Payments from drug & device makers

$9,031in general payments, 2019–2025

Across 646 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • GSK$1K
  • Novo Nordisk$867
  • Pfizer$723
  • Johnson & Johnson$606
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$9,026100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,031 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$16,842
Medicare patients
63
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$84,480
EliquisApixaban77$77,126
TrulicityDulaglutide51$47,207
JardianceEmpagliflozin36$37,531
FarxigaDapagliflozin Propanediol21$28,825
XareltoRivaroxaban11$11,777
Atorvastatin Calcium626$11,002
LinzessLinaclotide16$10,102
Rosuvastatin Calcium342$8,064
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$7,207
MyrbetriqMirabegron13$6,792
Spiriva RespimatTiotropium Bromide12$6,288
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,532
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$4,918
Levothyroxine Sodium286$4,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$867$84,48091 claims
PfizerEliquis$723$77,12677 claims
Lilly USA, LLCTrulicity$1,482$47,20751 claims
Boehringer IngelheimJardiance, Spiriva Respimat$572$43,81948 claims
AstraZenecaFarxiga$1,138$28,82521 claims
AbbVieLinzess, Synthroid$430$12,70140 claims
Johnson & JohnsonXarelto$606$11,77711 claims
Astellas Pharma US IncMyrbetriq$328$6,79213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →